daclatasvir
Selected indexed studies
- Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. (Clin Pharmacokinet, 2018) [PMID:29353349]
- Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation. (Expert Opin Pharmacother, 2023) [PMID:36369914]
- Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. (J Antimicrob Chemother, 2021) [PMID:33063117]
_Worker-drafted node — pending editorial review._
Connections
daclatasvir is a side effect of
Sources
- Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. (2018) pubmed
- Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation. (2023) pubmed
- Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. (2021) pubmed
- Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection. (2016) pubmed
- Daclatasvir for the treatment of chronic hepatitis C. (2015) pubmed
- Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment. (2022) pubmed
- Hepatoprotective drug screening identifies daclatasvir, a promising therapeutic candidate for MASLD by targeting PLIN2. (2025) pubmed
- Daclatasvir: A Review in Chronic Hepatitis C. (2016) pubmed
- Daclatasvir for the treatment of hepatitis C virus infection. (2014) pubmed
- Efficacy of daclatasvir in hepatitis C virus. (2014) pubmed